NCT05369793View on ClinicalTrials.gov

Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

October 10, 2023

Study Completion Date

October 10, 2023

Conditions
Type 2 Diabetes (Adult Onset)Diabetic Neuropathies
Interventions
DRUG

Alpha lipoic acid

Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.

DRUG

Roflumilast

Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.

Trial Locations (1)

31511

Asmaa Elshafey Elsharab, Tanta

All Listed Sponsors
lead

Tanta University

OTHER